呼吸道合胞病毒治疗和预防的药理学进展。
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
机构信息
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
出版信息
Clin Infect Dis. 2010 May 1;50(9):1258-67. doi: 10.1086/651603.
Abstract
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable. During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens. This article reviews these obstacles and presents the novel development strategies used to overcome many of them. Also discussed are promising new antiviral treatment candidates and their associated mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacologic manipulation of the host response to RSV disease.
摘要
目前，仅有 2 种药物被批准用于治疗呼吸道合胞病毒（RSV）。帕利珠单抗是一种用于预防高危儿童 RSV 的单克隆抗体。利巴韦林被批准用于治疗严重 RSV 疾病；然而，其改善结局的效果是有疑问的。在过去的 40 年中，许多障碍阻碍了安全有效的疫苗和治疗方案的发展。本文综述了这些障碍，并介绍了用于克服其中许多障碍的新的开发策略。还讨论了有前途的新型抗病毒治疗候选药物及其相关作用机制、疫苗开发方面的重大进展，以及通过对 RSV 疾病宿主反应的药物干预来改善结局的令人兴奋的新研究。
相似文献
1
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
Clin Infect Dis. 2010 May 1;50(9):1258-67. doi: 10.1086/651603.
2
Recent advances in the prevention and treatment of respiratory syncytial virus disease.
J Gen Virol. 2025 Apr;106(4). doi: 10.1099/jgv.0.002095.
3
New strategies for control of respiratory syncytial virus infection.
Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245.
4
Respiratory syncytial virus: prospects for new and emerging therapeutics.
Expert Rev Respir Med. 2017 Aug;11(8):609-615. doi: 10.1080/17476348.2017.1338567. Epub 2017 Jun 14.
5
Targeting RSV with vaccines and small molecule drugs.
Infect Disord Drug Targets. 2012 Apr;12(2):110-28. doi: 10.2174/187152612800100143.
6
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
7
A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.
J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S103-S109. doi: 10.1093/jpids/piae027.
8
Preventive and therapeutic strategies for respiratory syncytial virus infection.
Curr Opin Pharmacol. 2001 Oct;1(5):497-503. doi: 10.1016/s1471-4892(01)00087-x.
9
New Approaches to Respiratory Syncytial Virus Prevention and Treatment.
Annu Rev Med. 2025 Jan;76(1):13-28. doi: 10.1146/annurev-med-061323-073934. Epub 2025 Jan 16.
10
Up-to-date role of biologics in the management of respiratory syncytial virus.
Expert Opin Biol Ther. 2020 Sep;20(9):1073-1082. doi: 10.1080/14712598.2020.1753696. Epub 2020 Apr 17.
引用本文的文献
1
Advances in development of antiviral strategies against respiratory syncytial virus.
Acta Pharm Sin B. 2025 Apr;15(4):1752-1772. doi: 10.1016/j.apsb.2025.02.015. Epub 2025 Feb 20.
2
Trend of pathogens and respiratory co-infections in the province of Messina: from pediatric age to senescence.
J Prev Med Hyg. 2024 Oct 31;65(3):E344-E355. doi: 10.15167/2421-4248/jpmh2024.65.3.3344. eCollection 2024 Sep.
3
Respiratory Syncytial Virus Infection in Older Adults: An Update.
Drugs Aging. 2024 Jun;41(6):487-505. doi: 10.1007/s40266-024-01118-9. Epub 2024 May 7.
4
Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.
In Silico Pharmacol. 2023 Dec 24;12(1):5. doi: 10.1007/s40203-023-00178-w. eCollection 2024.
5
Respiratory Syncytial Virus Infection: Treatments and Clinical Management.
Vaccines (Basel). 2023 Feb 20;11(2):491. doi: 10.3390/vaccines11020491.
6
The Maresin 1-LGR6 axis decreases respiratory syncytial virus-induced lung inflammation.
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2206480120. doi: 10.1073/pnas.2206480120. Epub 2023 Jan 3.
7
Clinical and biological consequences of respiratory syncytial virus genetic diversity.
Ther Adv Infect Dis. 2022 Oct 8;9:20499361221128091. doi: 10.1177/20499361221128091. eCollection 2022 Jan-Dec.
8
Immunoinformatics-Aided Analysis of RSV Fusion and Attachment Glycoproteins to Design a Potent Multi-Epitope Vaccine.
Vaccines (Basel). 2022 Aug 24;10(9):1381. doi: 10.3390/vaccines10091381.
9
The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2598-2604. doi: 10.1080/14756366.2022.2123804.
10
RSV-associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomes.
Health Sci Rep. 2022 Apr 14;5(3):e556. doi: 10.1002/hsr2.556. eCollection 2022 May.
本文引用的文献
1
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.
2
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
BMC Infect Dis. 2009 Jul 5;9:106. doi: 10.1186/1471-2334-9-106.
3
Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.
Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
4
Challenges in developing a pediatric RSV vaccine.
Hum Vaccin. 2009 Sep;5(9):582-91. doi: 10.4161/hv.9131. Epub 2009 Sep 28.
5
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
J Infect Dis. 2009 Aug 1;200(3):439-47. doi: 10.1086/600108.
6
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.
Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62. doi: 10.1128/AAC.00014-09. Epub 2009 Jun 8.
7
Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus.
Clin Vaccine Immunol. 2009 Jun;16(6):859-65. doi: 10.1128/CVI.00033-09. Epub 2009 Apr 15.
8
Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
Curr Opin Mol Ther. 2009 Apr;11(2):208-18.
9
The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism.
J Virol. 2009 Jun;83(11):5353-62. doi: 10.1128/JVI.02374-08. Epub 2009 Mar 18.
10
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.
J Gen Virol. 2009 May;90(Pt 5):1119-1123. doi: 10.1099/vir.0.009308-0. Epub 2009 Mar 4.
Zotero 插件